Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2019 | Pages:
110 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global hunter syndrome treatment market size is expected to reach a value of USD 1.52 billion by 2026, expanding at a CAGR of 7.1%, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast period. Hunter syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According to the data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 to 150,000 male births. Presently, there are no approved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic relief and management of complications associated with disease progression. Shire plc’s Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea. Key players are focused on extensive R&D activities for product development and gaining approval as novel therapies. Launch of such novel therapies in the near future is expected to significantly fuel the Hunter syndrome treatment market growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA’s Fast Track designation for its novel drug candidate RGX-121, indicated for the disease treatment. Further Key Findings from the Study Suggest: • The enzyme replacement therapy segment has acquired the largest share in 2018, owing to the increased adoption of Elaprase and the potential approval of Hunterase worldwide • The absence of curative therapies for MPS II creates lucrative opportunities for the key players in the market for developing new therapies • The launch of late-stage pipeline therapies is expected to drive the market growth during the forecast period • Currently, Shire Plc. is one of the leading players, supported by strong sales of their marketed drug ELAPRASE for the disease treatment • Major players in the market are adopting inorganic growth strategies such as partnerships and collaborations for the development and commercialization of novel therapies • In 2018, North America held a dominant position in the global market, owing to favorable reimbursement scenario, high awareness regarding rare disorders, and presence of major players • Some of the key companies in hunter syndrome treatment market include GC Pharma, Sangamo Therapeutics, Inc.; JCR Pharmaceuticals Co Ltd.; RegenxBio Inc.; and Shire Plc. (Takeda Pharmaceutical Company)
Table of Content
Chapter 1 Methodology and Scope
1.1 Market segmentation & scope
1.2 Market definition
1.3 Information procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information analysis
1.4.1 Data analysis models
1.5 Market formulation & data visualization
1.6 Data validation & publishing
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Hunter Syndrome Treatment Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.2.1 User perspective analysis
3.2.1.1 Consumer behavior analysis
3.2.1.2 Market influencer analysis
3.3 Regulatory Framework
3.3.1 Reimbursement framework
3.3.2 Standards and compliances
3.4 Market Dynamics
3.4.1 Market driver analysis
3.4.1.1 Robust Pipeline & intorduction of novel therapies
3.4.1.2 Increasing government initatives
3.4.2 Market Restraint Analysis
3.4.2.1 High treatment cost
3.4.3 Industry challenges
3.5 Hunter Syndrome Treatment Market Analysis Tools
3.5.1 Industry analysis - Porter’s
3.5.1.1 Supplier Power
3.5.1.2 Buyer Power
3.5.1.3 Substitution Threat
3.5.1.4 Threat from new entrants
3.5.1.5 Competitive Rivalry
3.5.2 PESTEL Analysis
3.5.2.1 Political Landscape
3.5.2.2 Environmental Landscape
3.5.2.3 Social landscape
3.5.2.4 Technology landscape
3.5.2.5 Legal Landscape
3.5.3 Major deals and strategic alliances analysis
3.5.3.1 Joint ventures
3.5.3.2 Mergers and acquisitions
3.5.3.3 Licensing and partnership
3.5.3.4 Technology collaborations
3.5.3.5 Strategic Divestments
3.5.4 Market entry strategies
Chapter 4 Hunter Syndrome Treatment Market - Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Vendor Landscape
4.2.1 List of key distributors and channel partners
4.3 Public Companies
4.3.1 Key company market share analysis, 2018
4.4 Private Companies
4.4.1 List of key emerging companies
4.4.2 Regional network map
4.4.3 Company market position analysis
Chapter 5 Hunter Syndrome Treatment Market: Treatment Estimates And Trend Analysis
5.1 Definition & Scope
5.2 Treatment Market Share Analysis, 2018 & 2026
5.3 Segment Dashboard
5.4 Global Hunter Syndrome Treatment Market, by Treatment, 2015 to 2026
5.5 Market Size & Forecasts and Trend Analyses, 2015 to 2026
5.5.1 Enzyme Replacement Therapy (ERT)
5.5.1.1 Market Estimates and Forecasts, 2015 to 2026 (USD Million)
5.5.2 Hematopoietic Stem Cell Transplant (HSCT)
5.5.2.1 Market Estimates and Forecasts, 2015 to 2026 (USD Million)
5.5.3 Others
5.5.3.1 Market Estimates and Forecasts, 2015 to 2026 (USD Million)
Chapter 6 Hunter Syndrome Treatment Market: Regional Estimates & Trend Analysis
6.1 Regional Market Snapshot
6.2 Regional Market Share and Leading Players, 2018
6.2.1 North America
6.2.2 Europe
6.2.3 Latin America
6.2.4 Asia Pacific
6.2.5 Middle East & Africa
6.3 Market Share Analysis by Country, 2018
6.3.1 North America
6.3.1.1 U.S.
6.3.1.2 Canada
6.3.2 Europe
6.3.2.1 UK
6.3.2.2 Germany
6.3.2.3 Spain
6.3.2.4 France
6.3.2.5 Italy
6.3.2.6 Russia
6.3.3 Latin America
6.3.3.1 Brazil
6.3.3.2 Mexico
6.3.3.3 Argentina
6.3.4 Asia Pacific
6.3.4.1 Japan
6.3.4.2 China
6.3.4.3 India
6.3.4.4 South Korea
6.3.4.5 Australia
6.3.4.6 Singapore
6.3.5 Middle East & Africa
6.3.5.1 South Africa
6.3.5.2 Saudi Arabia
6.3.5.3 UAE
6.4 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
6.4.1 North America
6.4.2 Europe
6.4.3 Latin America
6.4.4 Asia Pacific
6.4.5 Middle East & Africa
6.5 Market Size & Forecasts, And Trend Analysis, 2018 To 2026
6.5.1 North America
6.5.1.1 Market Size & Forecasts and Trend Analysis, 2015 To 2026 (USD Million)
6.5.1.2 U.S.
6.5.1.2.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.1.3 Canada
6.5.1.3.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.2 Europe
6.5.2.1 Market Size & Forecasts and Trend Analysis, 2015 To 2026 (USD Million)
6.5.2.2 UK
6.5.2.2.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.2.3 Germany
6.5.2.3.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.2.4 Spain
6.5.2.4.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.2.5 France
6.5.2.5.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.2.6 Italy
6.5.2.6.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.2.7 Russia
6.5.2.7.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.3 Latin America
6.5.3.1 Market Size & Forecasts and Trend Analysis, 2015 To 2026 (USD Million)
6.5.3.2 Brazil
6.5.3.1.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.3.2 Mexico
6.5.3.2.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.3.3 Argentina
6.5.3.3.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.4 Asia Pacific
6.5.4.1 Market Size & Forecasts and Trend Analysis, 2015 To 2026 (USD Million)
6.5.4.2 Japan
6.5.4.2.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.4.3 China
6.5.4.3.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.4.4 India
6.5.4.4.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.4.5 South Korea
6.5.4.5.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.4.6 Australia
6.5.4.6.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.4.7 Singapore
6.5.4.7.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.5 Middle East & Africa
6.5.5.1 Market Size & Forecasts and Trend Analysis, 2015 To 2026 (USD Million)
6.5.5.2 South Africa
6.5.5.2.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.5.3 Saudi Arabia
6.5.5.3.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
6.5.5.4 UAE
6.5.5.4.1 Market Size & Forecasts and Trend Analysis, By Treatament, 2015 To 2026 (USD Million)
Chapter 7 COMPANY PROFILE
7.1 Company Profiles
7.1.1 Takeda Pharmaceutical Company
7.1.1.1 Company overview
7.1.1.2 Financial Performance
7.1.1.3 Product benchmarking
7.1.1.4 Strategic initiatives
7.1.2 GC Pharma
7.1.2.1 Company overview
7.1.2.2 Financial Performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic initiatives
7.1.3 JCR Pharmaceuticals Co Ltd.
7.1.3.1 Company overview
7.1.3.2 Financial Performance
7.1.3.3 Product benchmarking
7.1.3.4 Strategic initiatives
7.1.4 RegenxBio Inc.
7.1.4.1 Company overview
7.1.4.2 Financial Performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic initiatives
7.1.5 Sangamo Therapeutics, Inc.
7.1.5.1 Company overview
7.1.5.2 Financial Performance
7.1.5.3 Product benchmarking
7.1.5.4 Strategic initiatives
7.1.6 ArmaGen Inc.
7.1.6.1 Company overview
7.1.6.2 Financial Performance
7.1.6.3 Product benchmarking
7.1.6.4 Strategic initiatives
7.1.7 Inventiva S.A.
7.1.7.1 Company overview
7.1.7.2 Financial Performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic initiatives
7.1.8 Denali Therapeutics Inc.
7.1.8.1 Company overview
7.1.8.2 Financial Performance
7.1.8.3 Product benchmarking
7.1.9 Bioasis Technologies Inc.
7.1.9.1 Company overview
7.1.9.2 Financial Performance
7.1.9.3 Product benchmarking
7.1.9.4 Strategic initiatives
List of Tables Table 1 List of key distributors and channel partners Table 2 List of key emerging companies’/technology disruptors/innovators Table 3 North America Hunter syndrome treatment market, by country, 2015 - 2026 (USD Million) Table 4 North America Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 5 U.S. Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 6 Canada Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 7 Europe Hunter syndrome treatment market, by country, 2015 - 2026 (USD Million) Table 8 Europe Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 9 Germany Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 10 UK Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 11 Spain Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 12 France Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 13 Italy Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 14 Russia Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 15 Asia Pacific Hunter syndrome treatment market, by Country, 2015 - 2026 (USD Million) Table 16 Asia Pacific Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 17 Japan Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 18 China Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 19 India Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 20 South Korea Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 21 Australia Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 22 Singapore Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 23 Latin America Hunter syndrome treatment market, by country, 2015 - 2026 (USD Million) Table 24 Latin America Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 25 Brazil Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 26 Mexico Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 27 Argentina Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 28 MEA Hunter syndrome treatment market, by country, 2015 - 2026 (USD Million) Table 29 MEA Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 30 South Africa Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 31 Saudi Arabia Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) Table 32 UAE Hunter syndrome treatment market, by treatment, 2015 - 2026 (USD Million) List of Figures Fig. 1 List of Figures Fig. 2 Market research process Fig. 3 Data triangulation techniques Fig. 4 Primary research pattern Fig. 5 Primary interviews in North America Fig. 6 Primary interviews in Europe Fig. 7 Primary interviews in Asia Pacific Fig. 8 Primary interviews in Latin America Fig. 9 Primary interviews in MEA Fig. 10 Market research approaches Fig. 11 Value-chain-based sizing & forecasting Fig. 12 QFD modeling for market share assessment Fig. 13 Market formulation & validation Fig. 14 Sickle cell disease market snapshot (2018) Fig. 15 Parent market outlook Fig. 16 Ancillary market outlook Fig. 17 Penetration & growth prospect mapping, by treatment Fig. 18 Sickle cell disease market driver impact Fig. 19 Sickle cell disease market restraint impact Fig. 20 Sickle cell disease market challenges impact Fig. 21 Porter’s five force analysis Fig. 22 SWOT analysis, by factor (political & legal, economic and technological) Fig. 23 Sickle cell disease market share, by treatment, 2018 & 2026 (%) Fig. 24 Sickle cell disease market: Treatment segment dashboard Fig. 25 Enzyme Replacement Therapy (ERT) market, 2015 - 2026 (USD Million) Fig. 26 Hematopoietic Stem Cell Transplant (HSCT) market, 2015 - 2026 (USD Million) Fig. 27 Others market, 2015 - 2026 (USD Million) Fig. 28 Sickle cell disease market share, by region, 2018 & 2026 (%) Fig. 29 Sickle cell disease market: Regional outlook and key takeaways Fig. 30 North America market share, by country, 2018 Fig. 31 Europe market share, by country, 2018 Fig. 32 Asia Pacific market share, by country, 2018 Fig. 33 Latin America market share, by country, 2018 Fig. 34 Middle East & Africa market share, by country, 2018 Fig. 35 North America Hunter syndrome treatment market SWOT analysis Fig. 36 Europe Hunter syndrome treatment market SWOT analysis Fig. 37 Asia Pacific Hunter syndrome treatment market SWOT analysis Fig. 38 Latin America Hunter syndrome treatment market SWOT analysis Fig. 39 Middle East & Africa Hunter syndrome treatment market SWOT analysis Fig. 40 North America market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 41 U.S. market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 42 Canada market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 43 Europe market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 44 Germany market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 45 UK market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 46 France market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 47 Italy market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 48 Spain market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 49 Russia market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 50 Asia Pacific market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 51 Japan market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 52 China market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 53 India market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 54 South Korea market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 55 Australia market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 56 Singapore market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 57 Latin America market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 58 Brazil market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 59 Mexico market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 60 Argentina market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 61 Middle East and Africa market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 62 South Africa market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 63 Saudi Arabia market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 64 UAE market size, & forecasts and trend analysis, 2015 to 2026 (USD Million) Fig. 65 Heat map analysis, by key market participants Fig. 66 Participant categorization - Hunter syndrome treatment market Fig. 67 Public company market position analysis, 2018 Fig. 68 Public company market position analysis, 2018 Fig. 69 Regional network map
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
